The Drug Discovery Program focuses on the early stages of pharmaceutical R&D, from target discovery through to Phase I early clinical development. Taking part allows you to look at your company approach and performance across these phases compared to the industry.
Participating companies benefit from:
- a means of exploring the effect of different strategic approaches and practices in drug discovery
- a discussion forum through which they can debate, challenge and, in a culture of collaboration, explore interpretations of the emerging analyses
- a vehicle to gain access to reliable and comparable industry performance metrics in drug discovery
Each participating company will receive the exclusive Core Program Report, which provides company-specific insight into productivity, success and strategic approach in drug discovery.The Annual Strategy Workshop provides an excellent opportunity to discuss the report and other relevant topics with peers from across the industry. Focused surveys are also undertaken as a part of the program to address critical areas of interest, such as the use of biomarkers to aid decision making.
Learn more about Drug Discovery solutions from Thomson Reuters